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Objectives Serum CA72-4 levels are elevated in some gout patients but this has not been 
comprehensive described. The present study profiled serum CA72-4 expression in gout patients and 
verified the hypothesis that CA72-4 is a predictor of future flares in a prospective gout cohort.
Methods To profile CA72-4 expression, a cross-sectional study was conducted in subjects with gouty 
arthritis, asymptomatic hyperuricaemia, four major arthritis types (osteoarthritis [OA], rheumatoid 
arthritis [RA], spondyloarthritis [SpA], septic arthritis [SA]), and healthy controls. A prospective gout 
cohort study was initiated to test the value of CA72-4 for predicting gout flares. During a 6-month 
follow-up, gout flares, CA72-4 levels, and other gout-related clinical variables were observed at 1, 3, 
and 6 months. 
Results CA72-4 was highly expressed in patients with gouty arthritis (4.55 [1.56, 32.64] U/ml) 
compared with hyperuricaemia patients (1.47 [0.87, 3.29] U/ml), healthy subjects (1.59 [0.99, 3.39] 
U/ml), and other arthritis patients (SA, 1.38 [0.99, 2.66] U/ml; RA, 1.58 [0.95, 3.37] U/ml; SpA, 1.56 
[0.98, 2.85] U/ml; OA, 1.54 [0.94, 3.34] U/ml; P<0.001, respectively). Gout patients with frequent 
flares (≥2 times in the last year) had higher CA72-4 levels than patients with fewer flares (<2 times in 
the last year). High CA72-4 level (>6.9 U/ml) was the strongest predictor of gout flares (hazard 
ratio=3.889). Prophylactic colchicine was effective, especially for patients with high CA72-4 levels 
(P=0.014).
Conclusion CA72-4 levels were upregulated in gout patients who experienced frequent flares and 
CA72-4 was a biomarker to predict future flares.
Keywords: CA72-4, biomarker, gout, flare
Rheumatology key messages
 CA72-4 was specific upregulated in patients with gouty arthritis, but not with other major 
arthritis.
 High CA72-4 level (>6.9 U/ml) was the strongest predictor of gout flares.
 Prophylactic colchicine was effective, especially for gouty arthritis patients with high CA72-4 
levels (>6.9 U/ml).































































Gouty arthritis is one of the most common types of inflammatory arthritis, and is characterized by 
abrupt self-limiting attacks of inflammation arising from monosodium urate (MSU) crystal deposition 
in joints[1]. Hyperuricaemia is the prelude to gout. Only 10% of patients with hyperuricaemia develop 
gout, and high serum uric acid (sUA) level is not always associated with gout flares[2]. In gouty arthritis, 
MSU crystals induce NLRP3 inflammasome complex formation and the activation of IL-1β dependent 
innate inflammatory processes[3]. However, the inflammasome complex and IL-1β dependent 
inflammatory pathways are shared by gouty arthritis and other non-gout diseases, such as familial 
Mediterranean fever, type 2 diabetes mellitus, and Alzheimer disease[4]. Although some “triggers” of 
flares, including abrupt changes in sUA and cold, have been identified, biomarkers associated with 
gout inflammation are still unknown, which limits the prediction of gout flares[5].
CA72-4 is a commonly used cancer biomarker that was originally recognized as a tumor associated 
glycoprotein (TAG-72) by two monoclonal antibodies CC-49 and B72-3 in early studies[6, 7]. 
Subsequently, its epitope was identified as sialosyl-α(2-6)-N-acetylgalactosamine in contrast to 
peptide determinants[8, 9]. It was reported that CA72-4 is highly expressed gastric, ovary, breast, colon, 
lung, and pancreatic cancer tissues[10, 11]. In our dedicated gout clinic, CA72-4 levels were abnormally 
elevated in some gout patients during cancer screening, and almost all tumour diagnoses were 
subsequently excluded. Furthermore, one previous case report described aberrantly elevated serum 
CA72-4 levels in patients with gout flares[12]. However, there is no reasonable explanation for this 
phenomenon. Thus, we reviewed the serum CA72-4 levels in 37 diseases based on 38,526 laboratory 
tests in the Affiliated Hospital of Qingdao University, and found that the mean serum CA72-4 level 
was significantly higher in patients with gout than in patients with cancer[13]. Based on these findings, 
we designed a study to investigate the link between elevated serum CA72-4 and gouty arthritis, and to 
determine the potential role of CA72-4 in predicting flares.
Methods
Design
We initially conducted a cross-sectional study to profile serum CA72-4 expression levels in subjects 
with asymptomatic hyperuricaemia, gouty arthritis, and non-gouty arthritis (rheumatoid arthritis [RA], 
spondyloarthritis [SpA], osteoarthritis [OA], septic arthritis [SA]), and healthy controls. We then 






























































performed a 6-month prospective observational cohort study of the gout patients to test and verify the 
hypothesis that CA72-4 is a predictor of future flares. During the 6-month follow-up, gout flares, 
CA72-4 levels, and other gout-related clinical variables were observed at 1, 3, and 6 months. Other 
glycoprotein cancer markers including serum carcinoembryonic antigen (CEA), CA125, and CA19-9, 
were also examined in patients with gouty arthritis. The study was approved by the Ethics Committee 
of the Affiliated Hospital of Qingdao University and all study participants provided written informed 
consent.
Study population
Between June 2016 and May 2018, patients with gout or asymptomatic hyperuricaemia who visited 
the dedicated Gout Clinic at the Affiliated Hospital of Qingdao University were consecutively 
recruited, as were patients with RA, SpA, OA, or SA who visited the Department of Rheumatology. 
The diagnoses were confirmed by senior gout experts and rheumatologists. Gout patients were 
diagnosed according to the 2015 American College of Rheumatology/European League Against 
Rheumatism (ACR/EULAR) gout classification criteria[14]. Asymptomatic hyperuricaemia was 
defined as fasting sUA >7 mg/dl detected at least twice on 2 separate days in patients on a normal 
purine diet (defined as avoiding alcohol and purine-rich food such as seafood, red meat, especially 
organ meat, but not purine-rich leafy-green vegetables) without previous or current arthritis. RA 
patients included recent-onset and long-term patients who met the 2010 ACR/EULAR classification 
criteria[15]. SpA was diagnosed according to the Assessment of Spondyloarthritis International Society 
classification criteria[16]. Diagnoses of OA involving the hands and knees were established in 
accordance with two classification standards[17, 18]. SA was confirmed by synovial fluid germ culture 
or based on clinical assessments. Any patients manifesting sophisticated arthritis or with uncertain 
diagnosis according to the above criteria would not be recruited. Healthy controls, age and gender-
matched to gout patients, were recruited from the Health Examination Center at the hospital during the 
same period, and defined as persons with normal sUA, benign joint conditions, and no diagnosis of 
cancer or arthritis. All subjects were aged ≥18 years but were <80 years (Supplementary Table S1, 
available at Rheumatology online).
Informed consent and permission to use spare serum samples were obtained from all participants. All 
subjects had their serum CA72-4, sUA, and C-reactive protein (CRP) levels measured. Those with 
elevated CA72-4 were transferred to gastroenterologists and screened for neoplastic diseases. The 






























































exclusion criteria included: (a) presence or history of malignant disease; (b) pregnant or lactating 
women; (c) chronic renal failure (estimated glomerular filtration rate (eGFR) <15 ml/min/1.73 m2); 
and (d) hepatic dysfunction (alanine aminotransferase/total bilirubin greater than or equal to twice the 
upper limit of normal range).
Overall, 120 hyperuricaemia patients, 833 gout patients, 532 RA patients, 243 SpA patients, 474 OA 
patients, 43 SA patients, and 541 healthy controls were enrolled. Patients who refused to follow the 
procedure, withdraw their consent, or failed to meet the inclusion criteria for any other reason were 
excluded. 
Follow-up procedures
The gout cohort of 833 patients was followed for an additional 6 months after enrolment as a 
prospective study to verify whether CA72-4 is a predictor of gout flares. Patients were followed at 
baseline (time of enrolment), and at 1, 3, and 6 months after enrolment (Figure 1). All patients were 
treated with a standard protocol according to the 2012 ACR guidelines[19, 20]. Patients with a gout flare 
were treated with colchicine and/or nonst roidal anti-inflammatory drugs (NSAIDs) and sodium 
bicarbonate. Patients in the intercritical phase or beyond 2 weeks after the flare were started on urate-
lowering therapy (ULT) and prophylactic low-dose colchicine for 3 months. Patients who had no flares 
after 3 months of ULT ceased prophylactic colchicine. All patients were required to keep diaries of 
flares and medication compliance. Gout flares, CA72-4 levels, and other gout-related clinical variables, 
including medical history, presence or absence of tophi, body mass index (BMI), sUA, CRP, 
transaminase, fasting glucose, and eGFR, were collected at every visit. For the gout patients, serum 
CEA, CA125, and CA19-9 were also screened at baseline. 
Outcome measurements
The serum samples were spare samples in the hospital laboratory reserved for biochemical purposes. 
All samples were stored at −80°C for future use. The levels of CA72-4, CEA, CA125, and CA19-9 
were measured by an electrochemiluminescence method using Elecsys kits (CA72-4/11776258 122, 
CEA/11731629 322, CA125/11776223 190, CA19-9/11776193 122, Roche Diagnostic GmbH, 
Germany).). According to the kit instructions, the normal range of CA72-4, CEA, CA125, and CA 
19-9 were 0~6.9 U/ml, 0~3.4 ng/ml, 0~35 U/ml, and 0~39 U/ml, respectively. sUA and other 
biochemical parameters were detected by enzyme colorimetric methods. CRP was detected by a latex-
enhanced turbidimetric assay using reagents and instrumentation provided by Goldsite (Shenzhen, 
































































Baseline demographics and clinical features were summarized using standard descriptive statistics 
including the mean (standard deviation), or median (interquartile range), frequency or percent as 
appropriate. Comparisons of baseline demographic and clinical measures between different groups 
were undertaken using 2 tests, one-way ANOVA and Kruskal-Wallis tests as appropriate. Multiple 
linear regression models were developed to adjust confounders of the relationships between argument 
variables and dependent variables. Logistic regression models were developed to find predictors for 
independent variables. To estimate the influences of baseline variables and drug use on future flares in 
the prospective cohort, a multivariate analysis was performed using the COX proportional hazards 
model. The flare-free survival rates of patients with different CA72-4 levels (≤6.9 or >6.9 U/ml) were 
estimated by Kaplan–Meier curves. Receiver operating characteristic (ROC) curve analysis was used 
to test the performance of the gout flare prediction index. Two-sided tests with a 5% significance level 
(P<0.05) were considered statistically significant. All statistical analyses were performed using SPSS 
version 19.0 (IBM, Armonk, NY, USA).
Results
Profile of CA72-4 expression in the study population
Demographic data and baseline clinical characteristics among gouty and non-gouty arthritis, 
hyperuricaemia patients and healthy controls are shown in Supplementary Table S1, available at 
Rheumatology online. The descriptive statistics of CA72-4 in gout patients indicated a non-normal 
distribution (Figure 2A). The CA72-4 level in gout patients was significantly higher than that in 
healthy controls and hyperuricaemia patients (P<0.001), and 42.7% gout patients’ CA72-4 levels 
exceeded the upper limit of the normal reference range (>6.9 U/ml) (Figure 2A, 2B). Interestingly, 
patients who experienced only one flare in the last year before enrolment had similar CA72-4 levels 
with patients who did not have any flare, while patients with more frequent flares (≥2 per year)[21, 22] 
had higher serum CA72-4 levels than patients who experienced fewer flares (0 or 1 per year) (Figure 
2B). CA72-4 levels in asymptomatic hyperuricaemia patients and healthy subjects were within the 
normal reference range (Figure 2B). 
Most demographic and clinical variables were similar between the low (≤6.9 U/ml) and high (>6.9 






























































U/ml) CA72-4 groups, except for patients with flare (60.81% vs 70.91%, P=0.002), history of type 2 
diabetes (4.66% vs 16.34%, P<0.001), glucocorticoid use (14.83% vs 8.03%, P=0.001) and fasting 
glucose (5.28±0.81 mmol/L vs 5.96±1.46 mmol/L, P<0.001) at baseline (Table 1). After adjustment 
by multiple regression analysis, only flare frequency and fasting glucose were independently 
associated with CA72-4 (Supplementary Table S2, available at Rheumatology online).
By analysing the results of laboratory tests in patients with other common forms of arthritis (RA, OA, 
SpA, SA), we found the median CA72-4 levels in these four types of non-gouty arthritis (RA: 1.58 
[0.95–3.37] U/ml; OA: 1.54 [0.94–3.34] U/ml; SpA: 1.56 [0.98–2.85] U/ml; SA: 1.38 [0.99–2.66] 
U/ml) were comparable to those in healthy subjects (1.59 [0.99–3.39] U/ml) and much lower than in 
gouty arthritis patients (4.55 [1.56–32.64] U/ml, P<0.001) (Figure 2C). We also monitored sUA and 
CRP, a parameter reflecting overall inflammatory activity, and found that sUA levels were higher in 
gout and hyperuricaemia patients than in non-gouty arthritis patients (Supplementary Figure S1, 
available at Rheumatology online). CRP level in gouty arthritis was lower than that in SA, 
comparable to that in RA and SpA, and higher than that in OA patients. The CRP level in OA patients 
was similar with that in hyperuricaemia and healthy subjects (Supplementary Figure S2, available 
at Rheumatology online). 
Furthermore, serum CEA, CA 19-9, and CA 125 levels in gouty arthritis patients were within the 
normal limits (CEA: 2.04 [1.32, 2.96] ng/ml; CA19-9: 8.81 [7.01, 14.04] U/ml; CA125: 10.67 [7.48, 
14.47] U/ml), indicating that only CA72-4, but not other cancer glycoproteins, was highly expressed 
in gouty arthritis patients (Figure 2D). Taken together, CA72-4 was highly associated with gouty 
arthritis, particularly in patients with recent flares.
CA72-4 as a predictor of flares 
We prospectively followed the gout cohort. Of 833 gout patients, 722 completed 6 months of follow-
up visits and were included in the statistical analyses (Figure 1). Multiple linear regression analysis 
indicated that baseline CA72-4 and sUA, and the use of colchicine and glucocorticoids during the 
following 6 months were independently correlated with future flares (Table 2). Logistic regression 
analysis identified baseline CA72-4 (per 50 U/ml, OR=2.81, 95%CI (2.10–3.76), P<0.001), sUA 
(OR=1.12, 95%CI (1.04–1.21), P=0.003) and colchicine use (OR=0.59, 95%CI (0.42–0.82), P=0.002) 
as independent predictors for future flare risk (Figure 3A). Kaplan-Meier survival curves showed a 
lower cumulative flare-free survival rate at the end of 6 months in patients with high CA72-4 than with 






























































low CA72-4 (72.3% vs 10.7%, P<0.05) (Figure 3B). We investigated factors associated with the 
cumulated flares during the 6-months’ follow-up using a multivariable Cox proportional hazards model. 
Among nine biological variables potentially associated with flares, multivariable analysis identified 
high CA72-4 (>6.9 U/ml; HR=3.889) as the strongest factor to predict flares where as sUA above the 
median value (HR=1.373) and prophylactic colchicine (HR=0.759) were weak factors associated and 
inversely associated with flares, respectively (Figure 3B). CRP, tophi, triglyceride, BMI, NSAIDs, 
and fasting glucose were not significantly associated with gout flares (Supplementary Table S3, 
available at Rheumatology online).
In general, counting of flares based on CA72-4 level, baseline sUA level, and prophylactic colchicine 
indicated that CA72-4 was the major determinant of flares (Figure 3C, 3D). However, the probability 
of flares in patients with high sUA and high CA72-4 was higher than that in patients with high CA72-4 
and low sUA (Figure 3C). When CA72-4 was low, baseline sUA did not alter the flare frequency 
(Figure 3C). Although the use of colchicine in patients with high CA72-4 reduced the flare frequency 
(Figure 3D), colchicine did not alter the flare frequency when CA72-4 was low (Figure 3D). The 
presence of tophi had no effect on gout flare frequency, whereas CA72-4 level was critical for the gout 
attack (Supplementary Figure S3, available at Rheumatology online). Receiver operating 
characteristic (ROC) curve analysis showed that CA72-4 had the highest AUC among CA72-4, sUA, 
CRP and tophi (0.82, 95%CI (0.79–0.85); 0.57, 95%CI (0.52–0.60); 0.51, 95%CI (0.48–0.55); 0.51, 
95%CI (0.47–0.54), respectively, P<0.001) (Figure 4).
Discussion
CA72-4 is a mucin-like glycoprotein complex that can be identified by monoclonal antibody B72.3, a 
murine antibody raised against a membrane-enriched fraction from a human breast carcinoma liver 
metastasis[6, 7]. Despite all the efforts, CA72-4 has never been cloned[23, 24]. Evidences indicate that 
CA72-4 is not encoded by a single mucin gene, instead, the sialosyl-α(2-6)-N-acetylgalactosamine-α-
serine structures carried by the unknown mucin core protein is the antigen[8, 9]. Clinically, CA72-4 has 
been found in a variety of human adenocarcinomas[10, 25]. However, accumulating evidence has shown 
that elevated CA72-4 is expressed in malignant diseases as well as non-cancer diseases including 
pancreatic and biliary diseases, type 2 diabetes and liver disorders, indicating that CA72-4 is not a 
unique product of cancer cells[26, 27]. Actually, glycosylation is the most diverse and common 
posttranslational modification of proteins. In association with systemic abnormalities like cancer and 






























































gout, cell membrane glycan structures often exhibit dramatic changes and incomplete synthesis 
followed by accumulation of precursor structures are proposed to be responsible for generating the 
sialosyl-α(2-6)-N-acetylgalactosamine-α-serine structures[28, 29]. It will be critical to understand the 
molecular mechanisms underlying the increased CA72-4 levels in patients suffering gout. 
Inflammation is the common feature for all these non-cancer diseases, prompting an investigation of 
CA72-4 as well as other glycoprotein cancer biomarkers in such disorders. The present study 
demonstrated that CA72-4, a known cancer biomarker, was aberrantly highly expressed in gout 
patients. Therefore, we explored its clinical utility in predicting future flares in a prospective cohort 
study. Our initial discovery confirmed that mean serum CA72-4 levels in gout patients were much 
higher than those in healthy subjects and hyperuricaemia patients. Assuming ≤6.9 U/ml as the 
reference normal range, approximately 40% of gout patients had aberrantly high CA72-4 levels, and a 
few patients exceeded the detection limit (300 U/ml). CA72-4 belongs to a glycoprotein family that 
includes CA19-9, CA125, and CEA, which have been approved for monitoring various gastrointestinal 
and gynaecological malignancies[30]. We found that only CA72-4, and not the three other common 
cancer biomarkers, was elevated in gout patients. Similar results were reported by another study on an 
autoinflammatory disease, familial Mediterranean fever, in which patients also had elevated levels of 
CA72-4, but not the other three glycoproteins[31]. These data clearly indicate that elevated CA72-4 in 
this gout population was driven by gout itself rather than any cancer disorders. 
Hyperuricaemia predisposes patients to gout, but is largely asymptomatic[32]. Gout flares are self-
limiting and are followed by an intercritical phase. There are distinct clinical manifestations in terms 
of symptoms and parameters in laboratory tests among asymptomatic hyperuricaemia, acute gouty 
arthritis, intercritical phase gout and non-gouty arthritis patients. sUA level does not predict flares and 
is not a useful biomarker for gout diagnosis. CRP is a common marker for inflammation during gout 
flares. However, our study showed that CRP levels in gout patients were similar to that in RA and SpA 
patients, which diminished its value as a gout-specific marker. Generally, gouty arthritis lacks specific 
markers, unlike anti-citrullinated peptide antibodies in RA and positive germ culture in septic 
arthritis[33], which allow them to be distinguished from other forms of arthritis. We examined other 
major arthritis forms: RA, SpA, OA, and SA. Overall, CA72-4 levels were ranked from high to low in 
the order of gouty arthritis patients > hyperuricaemia patients = non-gouty arthritis patients = healthy 
subjects, indicating that high CA72-4 may be specific to gouty arthritis. 






























































The selective expression of CA72-4 was also distinct from the CRP expression pattern in gouty arthritis 
and non-gouty arthritis patients, implying that CA72-4 was gouty arthritis-dependent but independent 
from general inflammatory activity. However, CA72-4 levels were not high in hyperuricaemia patients, 
indicating that its level was related to a status prone to gouty activation rather than serum urate. 
Furthermore, patients with more frequent recent flares had much higher CA72-4 levels than patients 
with less frequent recent flares, indicating CA72-4 may reflect disease stability (active or relatively 
stable) in gouty arthritis. Therefore, CA72-4 levels might predict gout flares.
A 6-month prospective cohort study of enrolled gout patients was conducted to determine the 
predictive value of CA72-4 for future gout flares. Among the clinical variables analysed, sUA above 
median value (HR=1.373) was mildly associated with future gout flares, while prophylactic colchicine 
(HR=0.759) was negatively associated with gout flares, consistent with previous studies[34, 35]. As 
expected, CA72-4 (HR=3.889) was the strongest independent factor for predicting a flare in the 
prospective gout cohort. Logistic regression analysis confirmed that when CA72-4 increased per 50 
U/ml, the flare risk increased 2.81-fold. ROC curve analysis revealed that CA72-4 (AUC 0.82), but 
not sUA, CRP and presence of tophi (AUC 0.57–0.51), might predict gout flares. Thus, the prospective 
cohort study strongly supports the opinion that CA72-4 is a predictor of future gout flares. 
Gout attack may be triggered by cold, physical exhaustion, trauma or severe changes in serum urate 
levels. However, there is a lack of clinically useful predictors or prognostic factors for gout flares. To 
the best of our knowledge, CA72-4 is the first serum-derived biomarker that specifically indicates 
gouty arthritis and predicts flares in the near future. Whether tophi is a flare-predictor is 
controversial[36]. Our data imply that tophi is not a convincing indicator for colchicine use, because 
tophi were not associated with flares in the prospective cohort, whereas CA72-4 level, but not presence 
of tophi, determined gout flare frequency. Current opinion suggests tophi may predict flares during the 
initiation of ULT because of the potential release of urate from tophi and consequent re-crystallization. 
This is coincident with the EULAR and ACR recommendations on gout treatment, in which 
prophylactic colchicine is recommended during the initiation of ULT for 6 months in gout patients 
with tophi, even after achieving the target sUA level[14, 19]. Our data suggest that prophylactic 
colchicine provides flare protection in patients with high CA72-4 levels, but may not be required in 
patients with low CA72-4 levels.
Although the findings of this pilot study are promising, there is no biological mechanistic explanation 






























































for the link between CA72-4 and gouty arthritis. Baseline data in the gout cohort showed that patients 
with low CA72-4 levels had more glucocorticoid use, fewer flares, and lower blood glucose levels than 
patients with high CA72-4 levels. Either glucocorticoids had an impact on CA72-4 expression or 
patients with high levels of CA72-4 had severe disease as manifested in the prospective cohort and 
were more often treated with glucocorticoids. However, the logistic regression model and COX 
proportional hazards model confirmed that CA72-4, but not glucocorticoid use, was a predictor of gout 
flare. Based on these results, we hypothesize that glucocorticoid use lowers CA72-4 levels. 
Glucocorticoid is an anti-inflammatory drug with multiple targets including the NLRP3 inflammasome 
complex and subsequent IL-1β pathway, which is a major pathogenesis mechanism in gouty arthritis[37, 
38]. The current results suggest a potential relationship between CA72-4 and the NLRP3 inflammasome. 
Several studies support this hypothesis. Serum CA72-4 levels were elevated in patients with familial 
Mediterranean fever, a known NLRP3 inflammasome-related autoinflammatory disease, and were 
associated with the frequency of attacks[31]. Type 2 diabetes is considered to involve NLRP3-driven 
inflammation[39]. Shang et al., found that serum CA72-4 was related to hyperglycaemia as well as poor 
diabetes status[40]. Because CA72-4 is more likely a marker for immune pathway activation, it is 
reasonable to assume that glucocorticoid use will decrease CA72-4 levels. A prospective randomized 
trial is required to prove this.
One of the limitations of the present study was its observational nature. Because of the poor 
understanding of the mechanism for CA72-4 in gout, there is no way to identify a possible intervention 
with clear efficacy for the disease. Furthermore, CA72-4 can be influenced by many factors in addition 
to gouty arthritis; therefore, CA72-4 is unlikely to be well controlled in a randomized interventional 
study. Whether the findings of CA72-4 expression in the current study can be expanded to other races 
is uncertain, because all subjects in the current study were Chinese. Given the power of the sample 
size in the study, we could not observe a temporal relationship or exposure-based response for the 
predictive value of CA72-4.
In the current study, we observed the unexpected and specifically high expression of CA72-4 in gout 
patients with active status for flares. The present results have profound implications: 1) CA72-4 might 
be a useful routine test for gout management given its potential use as a marker reflecting gout stability, 
and thus indicating the chance of future flares; 2) high CA72-4 levels indicate a relatively active status 
in gouty arthritis and prophylactic colchicine should be administered to these patients during the 






























































initiation of ULT; 3) the biology of CA72-4 in gout warrants further investigation; and 4) the current 
data do not provide evidence that conventional ULT reduces CA72-4 levels in gout patients. CA72-4 
as a treatment target requires further investigation.
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Figure 1. Overall study design. Asterisk (*) represents unable to commit time, poor health condition, 
or subjected to surgery.
Figure 2. CA72-4 is elevated in patients with gouty arthritis. A. Distribution of gout patients with 
different serum CA72-4 levels (n=833). B. Comparison of serum CA72-4 levels among gout patients 
(n=833. Including no flares within 1 year, n=65); 1 flare within 1 year (n=691); ≥2 flares within 1 
year (n=77), hyperuricaemia patients (n=120), and healthy controls (n=541). C. Comparison of serum 
CA72-4 levels among gouty arthritis patients (n=833), septic arthritis patients (n=43), rheumatoid 
arthritis patients (n=532), spondyloarthritis patients (n=243), osteoarthritis patients (n=474), and 
healthy controls (n=541). D. Serum CA72-4, CEA, CA19-9, and CA125 levels in gout patients (n=195). 
Mann–Whitney U-test was used for statistical analyses of CA72-4 levels.
Figure 3. CA72-4 level-based prediction of future flares in a cohort of gout patients. A. Multiple 
logistic regression models were constructed for selected baseline variables to assess independence, 
priority, and confounding potentiality. B. Kaplan–Meier analysis of the accumulated flare-free survival 
curves according to CA72-4 level (≤6.9 or >6.9 U/ml). C. Number of flares in gout patients (n=722) 
with distinct CA72-4 levels (≤6.9 or >6.9 U/ml) and sUA levels (<420 or ≥420 mmol/L). D. Number 
of flares in gout patients (n=722) with distinct CA72-4 levels (≤6.9 or >6.9 U/ml) and prophylactic 
colchicine use. ANOVA was used for statistical analyses of flares among the various groups. Double 
asterisk (**) represents P<0.01.
Figure 4. Results of the receiver-operating characteristic curve analysis. The sensitivity and 
specificity of the four indexes are shown.































































Figure 1. Overall study design. Asterisk (*) represents unable to commit time, poor health condition, or 
subjected to surgery. 
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Figure 2. CA72-4 is elevated in patients with gouty arthritis. A. Distribution of gout patients with different 
serum CA72-4 levels (n=833). B. Comparison of serum CA72-4 levels among gout patients (n=833. 
Including no flares within 1 year, n=65); 1 flare within 1 year (n=691); ≥2 flares within 1 year (n=77), 
hyperuricaemia patients (n=120), and healthy controls (n=541). C. Comparison of serum CA72-4 levels 
among gouty arthritis patients (n=833), septic arthritis patients (n=43), rheumatoid arthritis patients 
(n=532), spondyloarthritis patients (n=243), osteoarthritis patients (n=474), and healthy controls (n=541). 
D. Serum CA72-4, CEA, CA19-9, and CA125 levels in gout patients (n=195). Mann–Whitney U-test was used 
for statistical analyses of CA72-4 levels. 
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Table 1. Demographic and baseline clinical characteristics in gout patients (n=833).
Characteristics CA72-4 ≤6.9 U/ml CA72-4 >6.9 U/ml P value
n 472 361
Age, years 50.07 (14.34) 49.18 (14.86) 0.384
Male, n (%) 422 (89.41) 328 (90.86) 0.488
BMI, kg/m2 27.47 (3.18) 27.40 (3.21) 0.831
Tophi, n (%) 88 (18.64) 65 (18.01) 0.814
Flare (within the last year), n (%) 287 (60.81) 256 (70.91) 0.002
aSmoking, n (%) 131 (27.75) 116 (32.13) 0.170
bDrinking, n (%) 290 (61.44) 206 (57.06) 0.202
cPhysical exercise, n (%) 126 (26.69) 114 (31.58) 0.123
dHypertension, n (%) 130 (27.54) 104 (28.81) 0.687
dCardiac disease, n (%) 20 (4.24) 16 (4.43) 0.891
dType 2 diabetes, n (%) 22 (4.66) 59 (16.34) <0.001
dNephrolithiasis, n (%) 28 (5.93) 16 (4.43) 0.891
eColchicines, n (%) 208 (44.07) 165 (45.71) 0.637
eNSAIDs, n (%) 128 (27.12) 99 (27.42) 0.922
eGlucocorticoids, n (%) 70 (14.83) 29 (8.03) 0.001
ULT, n (%) 168 (35.59) 135 (37.40) 0.592
ALT, U/L 27 (18, 43) 28 (18, 42) 0.762
AST, U/L 20 (17, 27) 21 (17, 27) 0.948
Glucose, mmol/l 5.28 (0.81) 5.96 (1.46) <0.001
TG, mmol/l 1.68 (1.19, 2.35) 1.74 (1.19, 2.51) 0.766
Cholesterol, mmol/l 4.51 (4.16, 5.31) 4.51 (4.16, 5.31) 0.465
Blood urea nitrogen, mmol/l 5.30 (4.00, 6.00) 5.30 (4.00, 6.00) 0.833
sCr, μmol/l 81.0 (71.0, 88.0) 81.0 (75.0, 90.5) 0.301
sUA, mg/dl 7.58 (2.18) 7.72 (2.26) 0.370
CRP, mg/l 5.61 (2.63, 25.11) 5.50 (3.12, 22.00) 0.301
BMI: body mass index; NSAIDs: non-steroidal anti-inflammatory drugs; ULT: urate-
lowering treatment; ALT: alanine aminotransferase; AST: aspartate aminotransferase; 






























































TG: triglyceride; sCr: serum creatinine; sUA: serum uric acid; CRP: C-reactive protein.
aAt least 20 cigarette packs in a lifetime or at least one cigarette a day for at least 1 year.
bAlcohol intake at least once a week for 6 months.
cMean cumulative exercise time per week of more than 30 min/day.
dHistory of hypertension, cardiac disease, type 2 diabetes, or nephrolithiasis.
eTreatment within 2 weeks before gout flare and blood sample collection.






























































Table 2. Multiple linear regression analysis of correlations between variables and 
flare frequency in a prospective gout cohort (n=722)
Variables B 95% CI P-value
Age, years -0.002 -0.008, 0.004 0.511
BMI, kg/m2 -0.008 -0.036, 0.021 0.588
Tophi present 0.018 -0.215, 0.252 0.876
CA72-4, U/ml 0.005 0.004, 0.006 <0.001
sUA, mg/dl 0.109 0.068, 0.150 <0.001
Glucose, mmol/l -0.008 -0.105, 0.089 0.869
aType 2 diabetes 0.187 -0.180, 0.554 0.316
TG, mmol/l 0.019 -0.052, 0.091 0.598
CRP, mg/l -0.001 -0.004, 0.002 0.374
bColchicines -0.321 -0.503, -0.139 0.001
bNSAIDs -0.213 -0.429, 0.002 0.053
bGlucocorticoids -0.411 -0.687, -0.136 0.004
aHistory of type 2 diabetes.
bTreatment during 6 months follow-up.
BMI: body mass index; sUA: serum uric acid; TG: triglyceride; CRP: C-reactive protein; 
NSAIDs: non-steroidal anti-inflammatory drugs.































































Figure 3. CA72-4 level-based prediction of future flares in a cohort of gout patients. A. Multiple logistic 
regression models were constructed for selected baseline variables to assess independence, priority, and 
confounding potentiality. B. Kaplan–Meier analysis of the accumulated flare-free survival curves according to 
CA72-4 level (≤6.9 or >6.9 U/ml). C. Number of flares in gout patients (n=722) with distinct CA72-4 levels 
(≤6.9 or >6.9 U/ml) and sUA levels (<420 or ≥420 mmol/L). D. Number of flares in gout patients (n=722) 
with distinct CA72-4 levels (≤6.9 or >6.9 U/ml) and prophylactic colchicine use. ANOVA was used for 
statistical analyses of flares among the various groups. Double asterisk (**) represents P<0.01. 
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Figure 4. Receiver-operating characteristic curve showing the capacity of CA72-4 (red), CRP (blue), sUA 
(pink), or tophi (green) to predict gout flares. The sensitivity and specificity of the four indexes are shown. 
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Male, n (%) 750 (90.04) 116 (96.67) 22 (51.16) 140 (26.32) 172 (70.78) 156 (42.98) 479 (88.54)
Age, years 50 (37-62) 42 (35-51) 51 (34-73) 64 (56-71) 44 (33-53) 63 (55-72) 52 (43-59)





























Glucose, mmol/l 5.32 (4.85-5.89) 5.47 (5.05-5.99) 5.50 (5.05-6.00) 5.67 (5.25-6.12) 5.54 (5.19-6.04) 5.63 (5.27-6.18) 4.41 (4.05-4.78)









































































































Glucocorticoid, n (%) 99 (11.88) 0 0 172 (32.33) 3 (1.23) 0 0
sUA: serum uric acid; ALT: alanine aminotransferase; AST: aspartate aminotransferase; TG: triglyceride; sCr: serum creatinine; CRP: C-reactive 
protein.






























































Supplementary Table 2. Multiple linear regression analysis of correlations 
between variables and CA72-4 level in gout patients (n=833)
Variables B 95% CI P-value
Age, years 0.155 -0.295, 0.605 0.499
BMI, kg/m2 -0.387 -2.395, 1.621 0.706
Tophi present -7.735 -24.096, 8.627 0.354
Flare frequencies 28.676 14.982, 42.371 <0.001
sUA, mg/dl -0.734 -3.651, 2.183 0.622
Glucose, mmol/l 15.878 8.688, 23.089 <0.001
aType 2 diabetes -6.715 -36.403, 22.972 0.657
bColchicine 3.580 -9.422, 16.582 0.589
bNSAIDs -2.852 -17.668, 11.964 0.706
bGlucocorticoid -16.758 -36.608, 3.093 0.098
aHistory of type 2 diabetes
bTreatment within 1 month before enrollment.
BMI: body mass index; sUA: serum uric acid; NSAIDs: non-steroidal anti-inflammatory 
drugs.






























































Supplementary Table 3. Multivariable Cox proportional regression analysis of 
explanatory variables for flare frequency during 6 months follow-up (n=722)
Variables P value HR 95% CI
CA72-4, U/ml 0.000 3.889 3.104-4.874
CRP, mg/l 0.680 0.958 0.782-1.174
Tophi present 0.765 1.040 0.804-1.347
TG, mmol/l 0.946 0.993 0.815-1.210
BMI, kg/m2 0.962 0.996 0.859-1.155
aNSAIDs 0.158 0.839 0.658-1.071
aGlucocorticoid 0.519 0.900 0.655-1.238
Glucose, mmol/l 0.733 1.060 0.757-1.185
aColchicine 0.007 0.759 0.621-0.927
sUA, mg/dl 0.002 1.373 1.124-1.677
All variables were categorical data. aTreatment during 6 months follow-up. The cut-off 
values were defined as: CA72-4: ≤ or > normal upper limit (6.9 U/ml); CRP: ≤ or > 
normal upper limit (5 mg/l); triglyceride: ≤ or > median level (1.69 mmol/l); BMI: 
≤ or > 24 kg/m2; glucose: ≤ or > normal upper limit (7.0 mmol/l); and sUA: ≤ or 
> median level (7.64mg/dl). CRP: C-reactive protein; TG: triglyceride; BMI: body 
mass index; NSAIDs: non-steroidal anti-inflammatory drugs; sUA: serum uric acid.






























































Supplementary Table 4. Spearman rank correlation coefficients between CA72-4 
level and other characteristics of gout patients (r (P))
CA72-4 CRP sUA Tophi
CRP -0.036 (0.328) -
sUA 0.028 (0.452) 0.106 (0.004) -
Tophi -0.047 (0.211) 0.060 (0.107) 0.034 (0.365) -
Age -0.046 (0.215) 0.144 (0.001) -0.054 (0.145) 0.022 (0.561)
CRP: C-reactive protein; sUA: serum uric acid.
Supplementary figure legends
Supplementary Figure S1. Comparison of sUA levels among acute gouty arthritis 
patients (n=833). 
Hyperuricaemia patients (n=120), SA patients (n=43), RA patients (n=532), SpA 
patients (n=243), OA patients (n=474), and healthy controls (n=541). ANOVA was 
performed for statistical analysis.
sUA: serum uric acid; SA: septic arthritis; RA: rheumatoid arthritis; SpA: 
spondyloarthritis; OA: osteoarthritis.
Supplementary Figure S2. Comparison of serum CRP levels among acute gouty 
arthritis patients (n=833), 
SA patients (n=43), RA patients (n=532), SpA patients (n=243), OA patients (n=474), 
hyperuricaemia patients (n=120) and healthy controls (n=541). The Mann–Whitney U-
test was performed for statistical analysis.
CRP: C-reactive protein; SA: septic arthritis; RA: rheumatoid arthritis; SpA: 
spondyloarthritis; OA: osteoarthritis.
Supplementary Figure S3. Comparisons of flare frequencies between gout patients 
(n=722).  The mean flare frequency within 6 months in the indicated groups is shown. 






























































ANOVA was performed for statistical analysis of flares among the various groups. 
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